069620 - Daewoong Pharma

069620 Summary

Biopharma

Stock Price & Overview

₩116,100 +1,300 (+1.13%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩116,100 ≈ US$83 · Market cap ₩1.3tn (≈ $961m)

069620 Financial Statements

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	1.57	1.42	1.38	1.28	1.15	1.06	1.11	1.03	0.96	0.88	0.84
Cost of Revenue	0.75	0.69	0.69	0.64	0.61	0.61	0.64	0.62	0.55	-0.51	-0.54
Gross Profit	0.82	0.73	0.69	0.64	0.54	0.45	0.48	0.41	0.41	0.37	0.30
Selling, General & Administrative	0.63	0.59	0.57	—	—	—	—	—	—	-0.35	-0.26
Operating Income	0.20	0.15	0.12	0.10	0.09	0.02	0.04	0.03	0.04	0.03	0.04
Finance Income	0.01	0.02	0.01	0.02	0.02	0.03	0.01	0.01	0.01	—	—
Finance Costs	0.04	0.04	0.03	—	—	—	—	—	—	—	—
Pretax Income	0.19	0.06	0.12	0.04	0.02	0.01	0.02	-0.00	0.04	0.03	0.05
Income Tax Expense	-0.00	0.03	0.00	-0.00	-0.01	-0.01	-0.01	0.01	0.00	-0.00	-0.01
Net Income	0.19	0.02	0.12	0.04	0.03	0.02	0.03	-0.02	0.04	0.03	0.04
Total Comprehensive Income	0.21	0.02	0.13	0.05	-0.02	0.04	0.03	-0.01	0.03	0.02	0.04

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	2.36	1.98	1.77	1.56	1.41	1.36	1.25	1.21	1.21	1.14	0.94
Current Assets	0.73	0.61	0.57	0.55	0.52	0.52	0.53	0.52	0.52	0.51	0.45
Cash & Cash Equivalents	0.17	0.10	0.11	0.10	0.08	0.07	0.03	0.07	0.09	0.08	0.06
Inventories	0.31	0.26	0.24	0.21	0.17	0.17	0.18	0.19	0.19	0.16	0.14
Trade Receivables	0.22	0.21	0.18	0.18	0.16	0.15	0.21	0.18	0.17	0.17	0.14
Non-current Assets	1.63	1.36	1.20	1.01	0.89	0.84	0.72	0.69	0.70	0.64	0.49
Property, Plant & Equipment	0.83	0.66	0.52	0.43	0.39	0.39	0.39	0.40	0.40	0.37	0.26
Intangible Assets	0.37	0.35	0.30	0.27	0.23	0.18	0.16	0.15	0.17	0.15	0.14
Total Liabilities	1.23	1.05	0.86	0.82	0.71	0.67	0.61	0.60	0.58	0.54	0.36
Current Liabilities	0.59	0.63	0.70	0.47	0.46	0.33	0.26	0.37	0.27	0.22	0.15
Non-current Liabilities	0.64	0.42	0.16	0.35	0.25	0.34	0.35	0.23	0.31	0.32	0.21
Total Equity	1.13	0.93	0.91	0.74	0.70	0.69	0.64	0.61	0.63	0.60	0.58
Share Capital	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Retained Earnings	0.83	0.64	0.62	0.50	0.47	0.45	0.45	0.42	0.44	0.42	0.40

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	149.2	51.5	136.0	118.2	40.0	101.0	57.6	47.5	103.9	15.4	35.9
Cash from Investing Activities	-247.0	-265.5	-165.6	-106.9	-87.7	-127.2	-85.6	-68.6	-73.0	-155.8	-108.6
Purchase of Property, Plant & Equipment	191.5	155.1	109.3	65.2	29.1	26.5	22.3	57.0	69.1	—	—
Cash from Financing Activities	164.4	200.6	39.2	15.5	50.2	66.6	-5.7	-4.8	-16.7	159.2	67.9
Dividends Paid	8.1	7.7	7.3	8.1	6.5	6.2	6.2	6.2	6.2	-7.2	-7.2
Net Change in Cash	66.0	-8.6	8.6	27.0	3.6	40.2	-33.2	-25.8	12.8	18.3	-3.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	448.5	377.8	397.1	411.8	405.4	356.5	367.9	358.5	360.5	335.8
Cost of Revenue	199.4	196.6	186.8	197.8	190.4	173.4	178.2	176.2	169.3	164.8
Gross Profit	249.1	181.2	210.4	214.0	215.1	183.1	189.7	182.3	191.2	171.0
Selling, General & Administrative	181.0	159.0	298.3	113.0	112.3	102.1	—	—	—	—
Operating Income	68.1	22.2	43.3	56.9	57.9	38.7	38.7	37.3	42.3	29.7
Finance Income	3.8	29.1	2.9	4.7	3.2	2.5	9.3	1.7	3.9	3.0
Finance Costs	9.9	6.2	12.1	3.1	12.9	9.5	—	—	—	—
Pretax Income	21.9	34.0	69.0	54.7	43.4	24.7	-9.8	27.4	27.6	11.3
Income Tax Expense	2.0	8.5	14.6	-7.4	-3.3	-5.0	1.7	-0.9	28.9	-3.4
Net Income	19.9	25.5	85.7	47.3	40.1	19.8	-11.5	28.3	-1.3	7.9
Total Comprehensive Income	36.8	28.0	120.2	50.7	26.0	9.4	-25.4	45.3	-25.5	26.0

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	2.54	2.45	2.36	2.26	2.11	1.99	1.98	1.92	1.88	1.81
Current Assets	0.76	0.74	0.73	0.79	0.71	0.62	0.61	0.57	0.59	0.56
Cash & Cash Equivalents	0.15	0.16	0.17	0.20	0.16	0.10	0.10	0.09	0.09	0.11
Inventories	0.32	0.31	0.31	0.31	0.30	0.27	0.26	0.25	0.25	0.25
Trade Receivables	0.26	0.22	0.22	0.22	0.22	0.22	0.21	0.20	0.22	0.17
Non-current Assets	1.78	1.71	1.63	1.47	1.40	1.37	1.36	1.35	1.29	1.24
Property, Plant & Equipment	0.92	0.88	0.83	0.75	0.68	0.66	0.66	0.62	0.59	0.55
Intangible Assets	0.39	0.38	0.37	0.37	0.37	0.35	0.35	0.33	0.32	0.30
Total Liabilities	1.35	1.30	1.23	1.26	1.15	1.06	1.05	0.97	0.97	0.88
Current Liabilities	0.86	0.66	0.59	0.68	0.64	0.59	0.63	0.54	0.62	0.69
Non-current Liabilities	0.49	0.64	0.64	0.57	0.52	0.47	0.42	0.43	0.35	0.19
Total Equity	1.19	1.15	1.13	1.00	0.95	0.93	0.93	0.95	0.91	0.93
Share Capital	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Retained Earnings	0.89	0.85	0.83	0.73	0.69	0.65	0.64	0.65	0.62	0.62

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	47.1	17.2	40.3	57.5	48.2	3.1	22.6	22.2	-9.3	16.0
Cash from Investing Activities	-74.6	-91.0	-107.4	-73.8	-43.9	-22.0	-78.2	-51.7	-77.5	-58.0
Purchase of Property, Plant & Equipment	43.6	74.3	89.5	58.7	23.1	20.2	48.5	30.9	38.4	37.4
Cash from Financing Activities	19.1	65.8	32.1	57.5	61.0	13.8	60.3	36.6	68.5	35.2
Dividends Paid	6.9	1.0	0.0	1.2	—	—	0.0	0.4	—	—
Net Change in Cash	-8.9	-5.3	-35.3	44.7	61.8	-5.2	8.4	6.9	-18.1	-5.7

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

069620 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	1,570.9	+10.4%	+7.1%	+8.3%	+6.5%
Operating income	196.8	+33.0%	+27.1%	+63.4%	+16.3%
Net income	192.9	+726.3%	+70.1%	+51.7%	+18.4%
EPS	₩16,649	+726.3%	+70.1%	+51.7%	+18.4%
Operating cash flow	149.2	+189.8%	+8.1%	+8.1%	+15.3%
Shareholders' equity	1,134.7	+22.4%	+15.2%	+10.4%	+6.9%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

069620 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	52.4%	51.6%	50.0%	49.9%	47.2%	42.3%
Operating margin	12.5%	10.4%	8.9%	7.5%	7.7%	1.6%
Net margin	12.3%	1.6%	8.7%	3.1%	2.6%	2.3%
Return on equity	18.7%	2.5%	14.5%	5.4%	4.3%	3.6%
Return on assets	8.9%	1.2%	7.2%	2.6%	2.2%	1.8%
Operating cash flow / revenue	9.5%	3.6%	9.9%	9.2%	3.5%	9.6%
Capex / revenue	12.2%	10.9%	7.9%	5.1%	2.5%	2.5%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 069620

Symbol	Last Price
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%
290650L & C BIO Co., Ltd.	₩47,900 -1.4%
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%
003090Daewoong Co., Ltd.	₩16,860 -2.0%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.